



10530736 - GAU: 1644

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/530,736 ✓
Filing Date	Jan 6, 2006
First Named Inventor	Catherine A. Phillips
Art Unit	1000
Examiner Name	To Be Assigned /Marianne DiBrino/
Attorney Docket Number	VET-1030-US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Transmittal (1 page); 2. IDS (1) Statement (2 pages); 3. SB/08 Form (4 pages); 4. References (38 items); and 5. Return Postcard (1 item).
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	BioTechnology Law Group		
Signature			
Printed name	Daniel M. Chambers		
Date	15 April 2007	Reg. No.	34,561

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Daniel M. Chambers	Date	15 April 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Phillips et al.

Serial No.: 10/530,736

Filed: Jan 6, 2006

Title: Detection, Localization and staging of Tumors Using Labeled Activated Lymphocytes Directed to a Tumor Specific Epitope

Examiner: To Be Assigned

Group Art Unit: 1600

Docket: VET-1030-US

INFORMATION DISCLOSURE STATEMENT (1)

Mail Stop: AMENDMENT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.


The listed documents are being submitted in compliance with 37 CFR § 1.97(b), before the mailing date of the first office action on the merits.

CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8:

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop: AMENDMENT, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Daniel M. Chambers
 (Printed Name)

15 April 2007
 (Date of Deposit)


 Signature

If any fees are due, please contact the undersigned attorney at (858) 350-9690.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date: 15 April 2007

BioTechnology Law Group

c/o PORTFOLIO

P.O. Box 52050


Minneapolis, MN 55402

Telephone: (858) 350-9690

Fax: (858) 350-9691

Email: dan@biotechnologylawgroup.com

By


Daniel M. Chambers

Reg. No. 34,561

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**


(Use as many sheets as necessary)

Complete if Known

Application Number	10/530,736
Filing Date	January 6, 2006
First Named Inventor	Catherine Phillips
Group Art Unit	1600
Examiner Name	To Be Assigned

Attorney Docket No: VET-1030-US

Sheet 1 of 4

**US PATENT DOCUMENTS**

Examiner Initials *	Cite No. ¹	USP Document Number	Issued Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	US 6,600,012	29 Jul 2003	Agrawal et al	
	A2.	US 6,490,476	03 Dec 2002	Sandrin et al	
	A3.	US 6,344,203	05 Feb 2002	Rubin et al	
	A4.	US 6,146,614	14 Nov 2000	Baltimore et al	
	A5.	US 5,840,859	24 Nov 1998	Lambert et al	
	A6.	US 5,814,295	29 Sep 1998	Martin, Jr. et al	
	A7.	US 4,735,210	05 Apr 1988	Goldenberg	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	A8.	WO 03077864	25 Sep 2003	DEPT OF VETERANS AFFAIRS, REHAB R & D SERVICE		
	A9.	WO 9850527	12 Nov 1998	BIOMIRA INC.		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A10.	ANDERS et al., "SPECT gallium-67 scanning in early human immunodeficiency virus (HIV) infection. Failure of scanning abnormalities to correlate with immunologic staging," <i>Clin. Nucl. Med.</i> 15:295-302 (1990)	
	A11.	BRADLEY et al., "Memory effectors: a potent, IL-4-secreting helper T cell population that develops in vivo after restimulation with antigen," <i>J Immunol</i> 150: 3119-3130 (1993)	
	A12.	BROSSART et al., "Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies," <i>Blood</i> 93(12):4309-17 (1999 Jun)	
	A13.	BRUNO et al., "On the cellular basis of immunological T cell memory," <i>Immunity</i> 2(1):37-43 (1995 Jan)	
	A14.	CHIN et al., "In vivo distribution of radio-labeled tumor infiltrating lymphocytes in cancer patients," <i>In Vivo</i> 7(1):27-30 (Jan-Feb 1993)	
	A15.	DILLMAN et al., "Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer," <i>Cancer Biother Radiopharm</i> 12(2):65-71 (1997 Apr)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)


Complete if Known

Application Number	10/530,736
Filing Date	January 6, 2006
First Named Inventor	Catherine Phillips
Group Art Unit	1600
Examiner Name	To Be Assigned

Sheet 2 of 4

Attorney Docket No: VET-1030-US

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A16.	FISHER et al., "Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma," <i>J Clin Oncol</i> 7(2):250-61 (1989 Feb)	
	A17.	GARDINER, "The therapeutic potential of synthetic multivalent carbohydrates," <i>Expert Opin Investig Drugs</i> 7(3):405-11 (1998 Mar)	
	A18.	GEYSEN et al., "Strategies for epitope analysis using peptide synthesis," <i>J. Immunol Methods</i> 102:259 (1987)	
	A19.	GRIFFITH et al., "In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma," <i>Natl Cancer Inst</i> 81(22):1709-17 (1989 Nov 15)	
	A20.	GRIMFORS et al., "Increased blood clearance rate of indium-111 oxine-labeled autologous CD4+ blood cells in untreated patients with Hodgkin's disease," <i>Blood</i> 76(3):583-9 (1990 Aug)	
	A21.	HILTBOLD et al., "Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells," <i>Cancer Res</i> 58(22):5066-70 (1998 Nov)	
	A22.	HOLLSBERG et al., "Increased blood clearance rate of indium-111 oxine-labeled autologous CD4+ blood cells in untreated patients with Hodgkin's disease," <i>Cell Immunol</i> 149(1):170-9 (1993 Jun)	
	A23.	KALOS, M., "Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects," <i>Vaccine</i> 2003 21(7-8):781-6. Review (2003 Jan)	
	A24.	KORF et al., "Divalent cobalt as a label to study lymphocyte distribution using PET and SPECT," <i>J Nucl Med</i> 39(5):836-41 (1998)	
	A25.	MAGARIAN-BLANDER et al., "Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1," <i>J Immunol</i> 160(7):3111-20 (1998 Apr)	
	A26.	MAZZONI et al., "Indium-labeled presensitized T cells for diagnosis of graft rejection," <i>J Surg Res</i> 52(1):85-8 (1992 Jan)	
	A27.	MUKHERJI et al., "Imaging pattern of previously in vitro sensitized and interleukin-2 expanded autologous lymphocytes in human cancer," <i>Int J Rad Appl Instrum B</i> 15(4):419-427 (1988) <i>Nucl. Med. Biol.</i> 	
	A28.	MULLER, C., "In vivo tracing of indium-111 oxine-labeled human peripheral blood mononuclear cells in patients with lymphatic malignancies," <i>J Nucl Med</i> 30(6):1005-11 (1989 Jun)	
	A29.	NELSON et al., "Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft," <i>J Immunol</i> 145(10):3507-15 (1990 Nov)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/530,736
Filing Date	January 6, 2006
First Named Inventor	Catherine Phillips
Group Art Unit	1600
Examiner Name	To Be Assigned

Sheet 3 of 4

Attorney Docket No: VET-1030-US

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A30.	PENG et al., "Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression." <i>J Immunol.</i> 165(10):5738-49 (2000 Nov)	
	A31.	PHILLIPS et al., "Trafficking as a consideration in adoptive immunotherapy: how does the route of administration affect the delivery of cytotoxic T lymphocytes to tumor?" <i>J. Immunology</i> 25(6):S34 (2002)	
	A32.	POCKAJ et al., "Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response," <i>Cancer</i> 73:1731-1737 (1994)	
	A33.	REYNOLDS et al., "Natural killer activity in the rat. IV. Distribution of large granular lymphocytes (LGL) following intravenous and intraperitoneal transfer," <i>Cell Immunol.</i> 86(2):371-80 (1984)	
	A34.	ROMERO et al., "Therapeutic cancer vaccines based on molecularly defined human tumor antigens," <i>Vaccine Suppl</i> 4:A2-7 (2002 Dec)	
	A35.	SANTIN et al., "Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer," <i>Gynecol Obstet Invest.</i> 49(3):194-203 (2000)	
	A36.	SARAGOVI et al., "Design and synthesis of a mimetic from an antibody complementarity-determining region," <i>Science</i> 253:792 (1991)	
	A37.	SPENCER et al., "Utilization of tumour-sensitized ('educated') and radiolabelled lymphocytes for tumour localization," <i>Nucl Med Commun.</i> 9(10):783-6 (1988 Oct)	
	A38.	STAUD et al., "Liver uptake and hepato-biliary transfer of galactosylated proteins in rats are determined by the extent of galactosylation," <i>Biochim Biophys Acta</i> 1427(2):183-92 (1999 Apr)	
	A39.	STEVENSON et al., "Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis," <i>Cancer Res.</i> 47(22):6100-3 (1987 Nov)	
	A40.	SWIFT et al., "Imaging of metastatic colorectal cancer with tumour-activated killer lymphocytes," <i>Lancet</i> 337(8756):1511-2 (1991).	
	A41.	TAYLOR-PAPADIMITRIOU et al., "MUC1 and cancer," <i>Biochimica et Biophysica Acta</i> 1455(2-3):301-313 (1999)	
	A42.	WAGSTAFF et al., "A method for following human lymphocyte traffic using indium-111 oxine labeling," <i>Clin Exp Immunol.</i> 43(3):435-42 (1981 Mar)	
	A43.	WAGSTAFF et al., "Human lymphocyte traffic assessed by indium-111 oxine labelling: clinical observations," <i>Clin Exp Immunol.</i> 43(3):443-9 (1981 Mar)	
	A44.	WRIGHT et al., "Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site," <i>J Immunother.</i> 23(1):2-10 (2000 Jan)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/530,736
Filing Date	January 6, 2006
First Named Inventor	Catherine Phillips
Group Art Unit	1600
Examiner Name	To Be Assigned

Sheet 4 of 4

Attorney Docket No: VET-1030-US

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A45.	WRIGHT et al., "Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells," <i>Int J Mol Med</i> . 9(4):401-4 (2002 Apr)	

EXAMINER

/Marianne DiBrino/

DATE CONSIDERED

12/07/2009

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./